Beryl Drugs Ltd vs Gujarat Terce Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Beryl Drugs Ltd is ₹ 20.1 as of 18 May 15:30 . The P/E Ratio of Beryl Drugs Ltd changed from 14.1 on March 2021 to 18.5 on March 2025 . This represents a CAGR of 5.58% over 5 yearsThe P/E Ratio of Gujarat Terce Laboratories Ltd changed from 22.2 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 years The Market Cap of Beryl Drugs Ltd changed from ₹ 3.35 crore on March 2021 to ₹ 10.68 crore on March 2025 . This represents a CAGR of 26.10% over 5 yearsThe Market Cap of Gujarat Terce Laboratories Ltd changed from ₹ 5.16 crore on March 2021 to ₹ 45.37 crore on March 2025 . This represents a CAGR of 54.46% over 5 years The revenue of Beryl Drugs Ltd for the Dec '25 is ₹ 3.85 crore as compare to the Sep '25 revenue of ₹ 5.16 crore. This represent the decline of -25.39% The revenue of Gujarat Terce Laboratories Ltd for the Dec '25 is ₹ 12.42 crore as compare to the Sep '25 revenue of ₹ 12.98 crore. This represent the decline of -4.31% The ebitda of Beryl Drugs Ltd for the Dec '25 is ₹ -0.2 crore as compare to the Sep '25 ebitda of ₹ 0.73 crore. This represent the decline of -127% The ebitda of Gujarat Terce Laboratories Ltd for the Dec '25 is ₹ 1.26 crore as compare to the Sep '25 ebitda of ₹ 1.94 crore. This represent the decline of -35.05% The net profit of Beryl Drugs Ltd changed from ₹ 0.37 crore to ₹ -0.17 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Gujarat Terce Laboratories Ltd changed from ₹ -0.08 crore to ₹ 0.76 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Beryl Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Gujarat Terce Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Beryl Drugs Ltd

Beryl Drugs Limited was incorporated on August 24, 1993.
The Company acquired the running business of M/s Flora and Fauna Remedies Limited on December 15, 1993.
The Shares of Company were listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange. The Company thereafter has been engaged in the manufacture, sale, and export of branded, generic pharmaceutical formulations in India and internationally.
It offers I.V. fluids, and a range of small and large volume injectables.
It provides a range of eye/ear drops, veterinary products, and injections.

About Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Limited, incorporated in 1985, is a trusted manufacturer of high quality medication at affordable rates for the common man.
Company specialise in producing oral solid dosages, including tablets and capsules, that address various therapeutic needs. Headquartered in Ahmedabad, Gujarat, Terce offers an extensive portfolio featuring over 125 products and more than 64 well-established brands. By 1986, Terce had established its presence in Gujarat and Rajasthan with a firm footing.
In 1992, the management raised public equity to give concrete shape and listed the Company on Bombay Stock Exchange.
In same year, Company established extensive manufacturing facility at Chhatral in Gandhinagar, Gujarat.
As India heralded new leaps in the pharma sector to become a global force to reckon with by 2005, the Company closely followed the narrative with ferocious growth expanding presence in the domestic and international market.

FAQs for the comparison of Beryl Drugs Ltd and Gujarat Terce Laboratories Ltd

Which company has a larger market capitalization, Beryl Drugs Ltd or Gujarat Terce Laboratories Ltd?

Market cap of Beryl Drugs Ltd is 10 Cr while Market cap of Gujarat Terce Laboratories Ltd is 28 Cr

What are the key factors driving the stock performance of Beryl Drugs Ltd and Gujarat Terce Laboratories Ltd?

The stock performance of Beryl Drugs Ltd and Gujarat Terce Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Beryl Drugs Ltd and Gujarat Terce Laboratories Ltd?

As of May 18, 2026, the Beryl Drugs Ltd stock price is INR ₹20.1. On the other hand, Gujarat Terce Laboratories Ltd stock price is INR ₹36.04.

How do dividend payouts of Beryl Drugs Ltd and Gujarat Terce Laboratories Ltd compare?

To compare the dividend payouts of Beryl Drugs Ltd and Gujarat Terce Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.